As you might know, scPharmaceuticals Inc. (NASDAQ:SCPH) last week released its latest third-quarter, and things did not turn out so great for shareholders. Revenues missed expectations somewhat, ...

SVB Securities analyst Roanna Ruiz maintained a Buy rating on scPharmaceuticals (SCPH - Research Report) today and set a price target of $12.00. The companys shares closed yesterday at $5.38. Ruiz ...

scPharmaceuticals, Inc. (SCPH) shares soared 8.8% in the last trading session to close at $5.84. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

scPharmaceuticals Inc. Annual stock financials by MarketWatch. View the latest SCPH financial statements, income statements and financial ratios.

scPharmaceuticals SCPH recently announced that the FDA approved its proprietary formulation of furosemide in 80 mg dosage delivered via an on-body infusor, marketed under the trade name Furoscix ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

In this article we will take a look at whether hedge funds think scPharmaceuticals Inc. (NASDAQ:SCPH) is a good investment right now. We check hedge fund and billionaire investor sentiment before ...

MannKind Corporation (MNKD) and scPharmaceuticals (SCPH) announced the signing of a definitive merger agreement for MannKind to acquire scPharmaceuticals. This proposed acquisition marks MannKind’s ...